COLLEGIUM PHARMACEUTICAL, INC (COLL) stock intrinsic value fair value estimate & owner earnings analysis

WHAT THE BUSINESS IS Collegium Pharmaceutical sells branded prescription medicines in the United States in two areas: pain and ADHD. In 2025 it booked $780.6 million of product sales: Belbuca (a buprenorphine film for chronic pain) $221.7 million, Xtampza ER (an abuse-deterrent extended-release oxycodone) $199.3 million, Nucynta IR and ER (tapentadol) $196.3 million, Jornay PM (currently the only FDA-approved stimulant dosed in the evening, acquired with Ironshore in September 2024) $148.9 million, and Symproic and other products $14.5 million. On May 12, 2026 the company bought a second ADHD medicine, Azstarys, from Corium for $655.6 million in cash at closing ($42 million of it placed in escrow), paid from $355.6 million of its own cash and a new $300 million term loan, plus up to $135 million of future milestone payments. Azstarys filled more than 760,000 prescriptions in 2025. Collegium built almost the whole portfolio by buying products and selling them through specialist sales forces of about 105 pain and about 200 ADHD representatives and managers. It does very little research of its own. Three customers accounted for 34%, 34% and 29% of 2025 revenue. WHAT IT EARNS We measure owner earnings as the cash the business produces from operations, minus short-term swings in working capital, minus stock-based pay (a real cost to shareholders), minus the small capital spending needed to keep running (under $2 million a year). On that basis Collegium earned $225.9 million in 2023 ($5.41 per diluted share), $226.5 million in 2024 ($5.60) and $283.3 million in 2025 ($7.14). Earlier years describe a smaller company, before it bought Belbuca's maker BDSI and Ironshore, the maker of Jornay PM. These figures are after interest paid on the company's debt. One accounting choice matters a lot: amortization of acquired product rights ($221.9 million in 2025) is a non-cash charge, so it is added back. Those rights are wasting assets, because each product loses exclusivity on a date we can see. So instead of treating today's earnings as permanent, we build each case product by product, using the cost structure the company actually showed in 2025, and let each product fade when its protection ends. THE DATES THAT DRIVE VALUE Nucynta: a third-party generic of Nucynta IR was approved in January 2026, and Collegium's authorized-generic partner Hikma launched a generic of IR on February 25, 2026, followed by ER. Nucynta sales, including the authorized generics, were $35.2 million in the second quarter of 2026, down 24% from a year earlier. Grunenthal, which licensed Nucynta to Collegium, sued in February 2026 claiming the authorized generic infringes its patents. The remaining Nucynta ER patents expire in 2028 and 2029. Belbuca: its patents expire in 2027 and December 2032. Alvogen, which earlier lost a challenge to the 2032 patent, told the company in June 2025 that its redesigned film does not infringe it. Collegium sued in July 2025, which delays FDA approval for up to 30 months, and trial is set for April 12, 2027. A second challenger, Ascent Pharmaceuticals, filed for a generic in June 2026 and Collegium sued it on July 16, 2026. Belbuca sales grew 10% in the second quarter. Xtampza ER: patents expire in 2030 and 2036, but sales fell 14% in the second quarter, and non-opioid competition is arriving, such as Vertex's suzetrigine, approved in January 2025 for acute pain. Jornay PM: sixteen patents expire in 2032, and sales grew 41% in the second quarter. Collegium also pays former Ironshore lenders 9.7% of Jornay net sales through March 2032, and we deduct that as a cost. Azstarys: most of its six listed patents run to December 2037. DEBT At June 30, 2026 Collegium owed $865.5 million of term loans, at about 7% interest, and $241.5 million of 2.875% convertible notes due February 15, 2029, convertible at $36.56 a share. It held $129.5 million of cash. The term loans require payments of $22 million for the rest of 2026, $66 million in each of 2027 and 2028 and $88 million in 2029, with $623.5 million due on December 23, 2030. That date can move forward to November 18, 2028 if the convertible notes are not dealt with and cash falls below set levels. Every product Collegium owns eventually loses its exclusivity, and none of our cases credits a replacement, so in every case the debt cannot simply be rolled over forever. In all three cases we therefore take the scheduled loan payments out of shareholders' cash as they fall due and charge interest only on what is still owed. The cash already on hand goes toward the first of those payments. We keep back $70 million as a working balance, about the company's lowest year-end cash balance in recent years ($70.6 million at December 31, 2024), which leaves about $60 million to apply to the debt. A loan can be refinanced at its maturity only where that case still has enough earning years left to pay it off afterwards, and every case repays all of the debt well before its earnings run out. Because the cash these products generate goes first to the lenders, all three values are lower than they would be for a business that could carry its debt indefinitely. BASE CASE, about $20 per share Nucynta falls to about $95 million in 2027 and fades to near zero by the mid-2030s. Xtampza declines about 8% a year, between its 4% first-half and 14% second-quarter declines in 2026, until generics after its 2036 patent. Belbuca grows to about $250 million in 2028, then generics arrive in 2029, when the 30-month delays against Alvogen and Ascent have run out, a middle path between losing the April 2027 trial and full protection to 2032. Jornay rises to about $310 million by 2031, extending its current growth at a slowing pace, then faces generics after 2032. Azstarys, on track for roughly $113 million of annual sales on the company's pro forma figures, grows about 4% a year to about $158 million, keeps about 45 cents of each sales dollar after its direct costs (against about 65 cents for the older pain products), and faces generics after 2037. We assume about $40 million of Azstarys milestone payments are earned. Together this gives 2026 owner earnings of roughly $210 million, pulled down by the Nucynta generics and Azstarys deal costs, after 25% growth in 2025. They recover to about $270 million in 2027, the first full year of Azstarys, then decline steadily as products lose protection. We give no value to future acquisitions, because the filings do not let us measure what past deals returned. On debt, the company makes the scheduled term-loan payments, repays the $241.5 million of convertible notes in cash in February 2029 (at this value the shares are worth less than the $36.56 conversion price, so holders would take cash), and refinances the $623.5 million due in December 2030, paying it off in equal installments from 2031 to 2035. That is before the Xtampza and Azstarys patents expire and while Azstarys and the remaining products still have years of earnings left. In total about $1.1 billion of product cash goes to lenders. BEAR CASE, about $6 per share Alvogen wins in April 2027 and generic Belbuca arrives in 2028, cutting its sales by more than half that year and further afterwards. Xtampza shrinks 12% a year. Jornay levels off at about $250 million. Azstarys stays near $110 million and keeps only about 40 cents of each sales dollar. Nucynta is nearly gone by 2030. The debt comes due just as earnings fall. The company makes the scheduled payments and repays the convertible notes in cash in 2029. With Belbuca gone generic, it can refinance only part of the 2030 balance: it pays the term loan down to about twice its following year's operating profit, at the top of its loan's interest-rate range, and clears the rest by 2032, when the Jornay patents expire. About $1.1 billion of product cash goes to lenders before shareholders see much, and what is left is mostly the Azstarys tail after 2032. Shareholders keep a small positive value, not a negative one: the portfolio still earns enough to pay the debt in full in this case. BULL CASE, about $41 per share Belbuca stays protected until December 2032 and keeps growing about 4% a year, close to its recent pace. Xtampza declines only about 4% a year. Jornay reaches about $385 million and Azstarys about $210 million, with all $135 million of milestones paid, as the combined ADHD sales force works both products. The company makes the scheduled term-loan payments and refinances the December 2030 balance, repaying it in equal installments from 2031 to 2035. At this value the shares are worth more than the $36.56 conversion price, so the convertible notes turn into about 6.6 million new shares instead of being repaid in cash, and we count them that way. WHAT COULD MAKE THIS WRONG The April 2027 Belbuca trial is the biggest single swing; protection to 2032 rather than generics in 2028 is worth roughly $16 per share. How fast Xtampza is declining, whether Azstarys grows under Collegium, and whether Jornay keeps growing matter nearly as much. Almost every product here is a wasting asset, the debt matures between 2028 and 2030, and the company paid for its latest acquisition partly with borrowed money, so the range of outcomes is wide. WHAT CHANGED SINCE OUR LAST ESTIMATE Our earlier estimate also repaid the debt from product cash, but it assumed the debt was paid off much faster than the loan agreements require (by about 2029 in its base case), and it credited the bull case with value from future acquisitions. We now repay the debt in every case exactly as the loan agreements require: scheduled installments, the convertible notes in February 2029 unless they turn into shares, and the December 2030 balance, which is refinanced and paid off only where the case's remaining earnings can cover it. We now give future acquisitions no value. The rest of the difference comes from a slightly faster Xtampza decline in the base case (8% a year rather than 7%) and from modeling each product's costs, the Jornay royalty and taxes explicitly. We also now use the cash the company already holds, less a working balance, toward the first loan payments. The result is a base value of about $20 per share, against about $24 before. The bear value is about $6, against about $3, and the bull value is about $41, against about $54. MARGIN-OF-SAFETY PRICE The bear case leaves little for shareholders and the portfolio is patent-exposed and leveraged, so the margin-of-safety price carries a large discount: about $10 per share, roughly half our base value. NOTES ON SOURCES Azstarys prescription and patent figures come from the company's March 19, 2026 acquisition announcement. The estimate of Azstarys annual sales is derived from the pro forma revenue in the company's second-quarter 2026 filing. Everything else comes from the company's annual and quarterly filings.